Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

The consensus market expectations are already baked in the share price — the reverse split followed by a secondary. The markets are not anticipating any monetary deals before this happens. Since their cash burden just went up due to NEO trials funding or lack of thereof, the need to raise cash accelerated. They need to do that within a month or so. The company probably expected the share price rise as they keep releasing some PRs , but absent any strong clinical data or cash deals the share price will be stagnant.
The company can not afford to wait until June 2019 when NEO or HOT data is available. PSA data is a wild card, however. We shall see.